Proactive Investors - Run By Investors For Investors

Imugene presenting all three immuno-oncology programs at AACR Annual Meeting

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive Investors about news the company's KEY-Vaxx and B-Vaxx cancer vaccine programs will be presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Lead candidate HER-Vaxx was tapped for inclusion last week, meaning that now all three of the clinical stage immuno-oncology company's programs will be featured.

 
View full IMU profile View Profile

Imugene Ltd Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use